A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

NCT06559722 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tested a combination injection of insulin degludec and liraglutide in adults with type 2 diabetes to see how it affected their blood sugar levels over 26 weeks.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 510 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-08 · est. completion 2026-02

What this study is testing ClinicalTrials.gov NCT06559722 ↗

Description as written by the study sponsor.

This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.

Treatments tested

Insulin Degludec/liraglutide Injection Drug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
XULTOPHY® Drug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

Main thing measured	Change from baseline in HbA1c after 26 weeks of treatment
Sponsor	Tonghua Dongbao Pharmaceutical Co.,Ltd
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06559722 ↗